1. Home
  2. SWKS vs HALO Comparison

SWKS vs HALO Comparison

Compare SWKS & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skyworks Solutions Inc.

SWKS

Skyworks Solutions Inc.

HOLD

Current Price

$88.68

Market Cap

10.2B

Sector

Technology

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$112.24

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWKS
HALO
Founded
1962
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
12.0B
IPO Year
1995
2001

Fundamental Metrics

Financial Performance
Metric
SWKS
HALO
Price
$88.68
$112.24
Analyst Decision
Hold
Buy
Analyst Count
15
11
Target Price
$70.38
$78.64
AVG Volume (30 Days)
6.6M
1.3M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
4.53%
N/A
EPS Growth
N/A
N/A
EPS
0.99
3.11
Revenue
$4,086,900,000.00
$151,862,000.00
Revenue This Year
N/A
$28.24
Revenue Next Year
$3.06
$12.56
P/E Ratio
$92.24
$35.27
Revenue Growth
N/A
N/A
52 Week Low
$51.93
$61.23
52 Week High
$92.30
$111.15

Technical Indicators

Market Signals
Indicator
SWKS
HALO
Relative Strength Index (RSI) 64.28 70.03
Support Level $54.32 $103.47
Resistance Level $92.30 N/A
Average True Range (ATR) 5.53 2.75
MACD 1.57 -0.63
Stochastic Oscillator 85.83 98.74

Price Performance

Historical Comparison
SWKS
HALO

About SWKS Skyworks Solutions Inc.

Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: